Pseudomalabsorption of levothyroxine.
OBJECTIVE
--The issue of patient compliance with pharmacological therapy vs malabsorption of medication was explored in the context of persistent hypothyroidism despite the administration of large doses of levothyroxine sodium.


METHODS
--Retrospective case series.


METHODS
--Referred care in two large tertiary care centers.


METHODS
--Four patients, seen within two decades, with clinical and biochemical hypothyroidism while receiving levothyroxine, were evaluated for selective malabsorption of this hormone.


METHODS
--Studies included serial measurements of thyroid hormone levels after a loading dose of levothyroxine or liothyronine sodium or evaluation with a double-labeled thyroxine tracer technique. Results were compared with studies of levothyroxine malabsorption in the medical literature.


RESULTS
--All patients were ultimately found to have normal (82% to 100%) absorption of oral levothyroxine. There was no evidence that malabsorption of levothyroxine can occur as an isolated abnormality.


CONCLUSIONS
--Some patients exhibit a factitious disorder suggesting malabsorption of levothyroxine. When treating hypothyroidism, psychiatric issues may result in noncompliance with levothyroxine therapy.
Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md.
K B
KB
Ain
S
S
Refetoff
H G
HG
Fein
B D
BD
Weintraub
D000328:Adult; D005162:Factitious Disorders / Q000175:diagnosis; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000378:metabolism*; D007408:Intestinal Absorption; D008875:Middle Aged; D010349:Patient Compliance; D012189:Retrospective Studies; D013974:Thyroxine / Q000097:blood / Q000493:pharmacokinetics*; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D013974:Thyroxine